Local clinician
You can start with a general practitioner, obesity specialist or endocrinologist. In-person care can make examination, laboratory testing and referrals easier.
Modern obesity treatment in Europe
Obesity care. Start with clear information.
Understand treatment, costs and medical care. No miracle-weight-loss promises and no medication sales. Start with the question that matters to you.
Affiliate link: WeightGuide may earn a referral commission. Confirm any discount and its terms directly with the provider.
✓ EU regulatory sources✓ No medicine sales✓ Clinician-led treatment
01 · Orientation
Calculate your BMI
Enter height and weight for an adult BMI estimate. BMI is only one part of a clinical assessment.
BMI is not a diagnosisIt does not capture age, body composition, fat distribution or your full medical situation.
—BMI
02 · Treatment pathway
Obesity treatment is more than one intervention
Lifestyle measures remain important, while prescription medication or specialist care may be appropriate for some people after clinical assessment.
- 01Foundation
Lifestyle support
Nutrition, physical activity, sleep and sustainable behavioural changes.
- 02Additional option
Obesity medicines
Prescription treatment may include GLP-1 and related medicines when clinically appropriate.
- 03Specialist care
When more support is needed
Specialist obesity services can combine medical, nutritional, psychological and surgical options.
GLP-1 and weight loss: what the term actually means
GLP-1 is a hormonal signal involved in appetite, food intake and metabolism. Some medicines mimic this pathway, while others combine it with additional hormonal activity.
GLP-1 and weight loss: what the term actually means
GLP-1 is a hormonal signal involved in appetite, food intake and metabolism. Some medicines mimic this pathway, while others combine it with additional hormonal activity.
Wegovy and weight management: what to know about semaglutide
Wegovy contains semaglutide and is authorised in the EU for weight management in defined patient groups. Since 2026, EU product information includes both weekly injections and daily oral tablets for adults.
Mounjaro and weight management: what to know about tirzepatide
Mounjaro contains tirzepatide. In the EU it has an authorised indication for weight management in defined groups of adults, in addition to its type 2 diabetes indication.
Wegovy tablets: the first oral GLP-1 treatment for weight management in the EU
In 2026 Wegovy was extended in the EU to include oral tablets for adults. The active ingredient remains semaglutide, but the formulation and dosing schedule differ from the weekly injection.
Saxenda · liraglutide
GLP-1 · EMA ↗
Ozempic
In the EU, Ozempic is authorised for type 2 diabetes. Semaglutide for weight management is authorised as Wegovy.
EMA ↗How a clinician decides
Before prescribing an obesity medicine, a clinician reviews factors such as BMI, medical history, other conditions, current medicines and potential risks. Only then can they decide whether treatment is appropriate.
Safety and sourcing
Prescription medicines should be obtained through a legal supply chain after appropriate clinical assessment. Unverified websites, marketplaces and social media offers can expose people to counterfeit products, poor storage or uncertain ingredients.
Online obesity treatment: what to expect from a medical consultation
Telemedicine can make an initial clinical assessment and follow-up more accessible. Discreet online consultation with the possibility of a prescription if a doctor considers the treatment appropriate after an individual assessment. Treatment must be based on an individual assessment and the rules of the country where care is provided.
Online obesity treatment: what to expect from a medical consultation
Telemedicine can make an initial clinical assessment and follow-up more accessible. Discreet online consultation with the possibility of a prescription if a doctor considers the treatment appropriate after an individual assessment. Treatment must be based on an individual assessment and the rules of the country where care is provided.
→03 · Popular searches
Explore the topics people look for most
Detailed pages answer high-intent questions without turning medicine names into sales claims.
Weight-loss injections
GLP-1, Wegovy, Mounjaro and how injectable obesity treatment works.
Mounjaro vs Wegovy
Compare tirzepatide and semaglutide.
Mounjaro price
Why cost varies across Europe and how to verify it.
Wegovy price
Local pricing, reimbursement and safe sourcing.
Wegovy tablets
2026 update: oral semaglutide is now part of the EU Wegovy authorisation.
GLP-1 explained
Understand the mechanism and key medicines.
Online obesity treatment
What a remote clinical assessment may involve.
Local clinical care
A GP, obesity specialist or endocrinologist can assess medical risk, local medicine availability and the need for tests or specialist referral.
affiliate option
Online medical consultation
Remote assessment can be convenient for some people. Discreet online consultation with the possibility of a prescription if a doctor considers the treatment appropriate after an individual assessment. The clinician decides whether treatment is appropriate and safe.
How consultation worksAffiliate link: WeightGuide may earn a referral commission. Confirm any discount and its terms directly with the provider.Myths and facts about weight-loss injections
Myth
“It is only about willpower.”
Fact
Body weight is influenced by biological, psychological, social and environmental factors. Treatment should be individual and long-term.
Myth
“Injections replace diet and physical activity.”
Fact
Obesity medicines are authorised as an addition to lifestyle measures, not as a replacement for them.
Myth
“Ozempic is the European weight-loss medicine.”
Fact
In the EU, Ozempic is authorised for type 2 diabetes. Semaglutide for weight management is authorised as Wegovy.
Myth
“A higher dose always means a better result.”
Fact
Dose escalation depends on the medicine, tolerability and medical judgement. Do not change the dose yourself.
Myth
“Everyone who is overweight should receive a medicine.”
Fact
Treatment is considered according to BMI, weight-related conditions, risks and overall health.
Myth
“The result must come immediately.”
Fact
Response varies between people. A clinician reviews benefit, adverse effects and the next steps over time.
04 · Common questions
Frequently asked questions about obesity medicines in Europe
Who may be eligible for prescription obesity medicines?
For some EU-authorised medicines, adult weight-management treatment is indicated from a BMI of 30 kg/m², or from 27 to under 30 kg/m² when at least one weight-related comorbidity is present. A clinician still needs to assess individual suitability.
What is the difference between Wegovy and Ozempic?
Both contain semaglutide, but their authorised uses differ. Wegovy is authorised for weight management in defined groups, while Ozempic is authorised in the EU for insufficiently controlled type 2 diabetes.
What is Mounjaro?
Mounjaro contains tirzepatide, which acts on GIP and GLP-1 receptors. It has EU indications for type 2 diabetes and for weight management in defined groups of adults.
Are Wegovy tablets available in the EU?
EMA product information updated in August 2026 includes Wegovy given by injection or as oral tablets for adults. Actual market availability, price and reimbursement can still differ by country.
Can an online consultation include a prescription?
No. A clinician may decide that a medicine is not appropriate, that more information is needed or that in-person assessment is preferable. Prescribing also depends on local rules.
Sources and review
BMI thresholds and limitations are based on public health guidance. BMI is a screening measure and does not replace clinical assessment.